HIV Diagnostics Market Outlook 2030: Key Developments and Future Scope

HIV Diagnostics Market Report Overview:

The global HIV diagnostics market is projected to expand at a CAGR of approximately 10% over the forecast period. Market growth is being fueled by the rising global prevalence of HIV, supportive government programs, increased awareness around the importance of early detection, and the growing use of rapid self-testing kits and point-of-care diagnostic solutions.

Download Sample PDF: https://meditechinsights.com/hiv-diagnostics-market/request-sample/

Despite this momentum, the adoption of HIV testing continues to face challenges. High costs associated with advanced diagnostic technologies, inadequate healthcare infrastructure in low- and middle-income countries, and persistent social stigma surrounding HIV remain significant barriers to broader market penetration.

HIV diagnostics encompass a range of methods used to detect the presence of the Human Immunodeficiency Virus (HIV). Timely and accurate diagnosis is essential not only for initiating the right treatment but also for preventing further transmission within communities. Key HIV diagnostic methods include:

• Antibody Tests: The most common initial screening tools, designed to detect antibodies produced by the immune system in response to HIV infection.
• Antigen/Antibody Combination Tests: Also known as 4th-generation tests, these detect both HIV antibodies and the p24 antigen—one of the earliest markers of infection—allowing for faster identification compared to antibody-only tests.
• Nucleic Acid Tests (NATs): Highly sensitive tests that detect the viral RNA in the bloodstream. NATs are crucial for early diagnosis and for monitoring viral load in individuals living with HIV.
• Rapid Diagnostic Tests (RDTs): Point-of-care tests that provide results within 20–30 minutes using blood or oral fluid samples. Their speed and simplicity make them ideal for community outreach and mobile testing.
• Self-Testing Kits: At-home kits that allow individuals to collect their own samples and test privately. These significantly improve accessibility and help reduce the stigma associated with clinical testing environments.

Collectively, these diagnostics play a vital role in HIV prevention, treatment, and long-term disease management by enabling timely intervention and reducing transmission rates.

Competitive Landscape

The global HIV diagnostics market is highly competitive, featuring both established companies and emerging innovators. Key players include:

• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• BioMérieux S.A.
• Siemens Healthineers
• Danaher Corporation
• OraSure Technologies
• Chembio Diagnostics Inc.
• Becton, Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Hologic, Inc.

To strengthen their market position, companies are focusing on product innovation, strategic partnerships, collaborations, and geographic expansion.

Download the PDF brochure to learn more about this report.

Government Initiatives & Global Funding: Expanding Access to HIV Testing

Government programs and international funding initiatives are key drivers of the HIV diagnostics market. Public health agencies worldwide are partnering with governments to expand access to HIV testing through subsidized programs, large-scale screening campaigns, and improved healthcare infrastructure.

Major efforts include:

• PEPFAR (U.S. President’s Emergency Plan for AIDS Relief): A landmark initiative that has significantly increased global HIV testing and facilitated millions of screenings worldwide.
• The Global Fund: Providing financial and operational support for HIV testing programs, particularly in high-burden regions such as sub-Saharan Africa and Southeast Asia.
• National Government Actions: Countries like South Africa and Brazil have integrated HIV testing into routine public healthcare, expanding outreach through mobile clinics and point-of-care technologies.

In addition to expanding access, governments are accelerating regulatory approvals and funding research and innovation to promote more advanced HIV diagnostic technologies.

Examples of recent developments include:

• Dec 2024: The Global Fund and PEPFAR launched a coordinated effort to supply lenacapavir, a long-acting injectable PrEP, to 2 million people over three years. This initiative is supported by the Children’s Investment Fund Foundation and the Bill & Melinda Gates Foundation.
• Jan 2024: The Global Fund approved US$9.2 billion in new grants for HIV and other disease-related testing and awareness programs across more than 70 countries—aimed at strengthening healthcare systems and expanding access to essential diagnostics.

Download Sample PDF: https://meditechinsights.com/hiv-diagnostics-market/request-sample/

From Clinics to Comfort: The Rapid Shift Toward HIV Self-Testing

HIV self-testing has grown rapidly in recent years, propelled by technological advancements and a stronger emphasis on privacy, convenience, and accessibility. Modern self-test kits—such as those using oral swabs—provide results in about 20 minutes with high accuracy, reducing the discomfort associated with blood-based tests.

Governments and global health organizations now increasingly integrate self-testing into public health strategies to improve early detection and reduce stigma. Offering individuals the ability to test privately at home has proven especially impactful for populations hesitant to visit clinics.

Notable milestones include:

• Jan 2025: OraSure Technologies received FDA approval for the OraQuick HIV Self-Test for individuals aged 14 and older, expanding youth access in the U.S.
• Jun 2023: Newfoundland Diagnostics partnered with Atomo Diagnostics to supply HIV rapid self-test kits in retail stores such as Tesco across the UK/EU—the first mainstream retail rollout in Europe.
• Apr 2023: Abbott partnered with Population Services International (PSI) to offer low-cost HIV self-test kits in low- and middle-income countries, helping reduce stigma and increase accessibility.

HIV Diagnostics Market – Segmentation

Download the PDF brochure to explore the full market segmentation.

Browse Research Report: https://meditechinsights.com/hiv-diagnostics-market/

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com